Researchers Strive to Refine TMB.

Increasingly, oncologists are turning to tumor mutation burden (TMB) as a biomarker of response to immune checkpoint inhibitors. However, recent research suggests that TMB needs to be further refined before it can be adopted broadly across tumor types and patient populations.